Advertisement

International Journal of Hematology

, Volume 107, Issue 6, pp 615–623 | Cite as

Chinese guidelines for treatment of adult primary immune thrombocytopenia

  • Xin-guang Liu
  • Xiao-chuan Bai
  • Fang-ping Chen
  • Yun-feng Cheng
  • Ke-sheng Dai
  • Mei-yun Fang
  • Jian-Ming Feng
  • Yu-ping Gong
  • Tao Guo
  • Xin-hong Guo
  • Yue Han
  • Luo-jia Hong
  • Yu Hu
  • Bao-lai Hua
  • Rui-bing Huang
  • Yan Li
  • Jun Peng
  • Mi-mi Shu
  • Jing Sun
  • Pei-yan Sun
  • Yu-qian Sun
  • Chun-sen Wang
  • Shu-jie Wang
  • Xiao-min Wang
  • Cong-ming Wu
  • Wen-man Wu
  • Zhen-yu Yan
  • Feng-e Yang
  • Lin-hua Yang
  • Ren-Chi Yang
  • Tong-hua Yang
  • Xu Ye
  • Guang-sen Zhang
  • Lei Zhang
  • Chang-cheng Zheng
  • Hu Zhou
  • Min Zhou
  • Rong-fu Zhou
  • Ze-ping Zhou
  • Hong-li Zhu
  • Tie-nan Zhu
  • Ming Hou
Guide Line

Abstract

Primary immune thrombocytopenia (ITP) is a bleeding disorder commonly encountered in clinical practice. The International Working Group (IWG) on ITP has published several landmark papers on terminology, definitions, outcome criteria, bleeding assessment, diagnosis, and management of ITP. The Chinese consensus reports for diagnosis and management of adult ITP have been updated to the 4th edition. Based on current consensus positions and new emerging clinical evidence, the thrombosis and hemostasis group of the Chinese Society of Hematology issued Chinese guidelines for management of adult ITP, which aim to provide evidence-based recommendations for clinical decision making.

Keywords

Primary immune thrombocytopenia Guideline Diagnosis, management 

Notes

Acknowledgements

Alexandra H. Marshall (of Marshall Medical Communications) provided editorial assistance to the authors during preparation of this manuscript.

Compliance with ethical standards

Conflict of interest

The authors have no competing financial interests to declare.

Supplementary material

12185_2018_2445_MOESM1_ESM.pdf (422 kb)
Supplementary material 1 (PDF 421 kb)

References

  1. 1.
    Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–80.PubMedGoogle Scholar
  2. 2.
    Terrell DR, Beebe LA, Neas BR, Vesely SK, Segal JB, George JN. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012;87(9):848–52.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–15.CrossRefPubMedGoogle Scholar
  4. 4.
    British Committee for Standards in Haematology General Haematology. Task F: guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574–96.CrossRefGoogle Scholar
  5. 5.
    Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.CrossRefPubMedGoogle Scholar
  6. 6.
    Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.CrossRefPubMedGoogle Scholar
  7. 7.
    Chinese Society of Hematology GoTaH. Consensus Of Chinese Specialists On the diagnosis and treatment of the adult primary immune thrombocytopenia. Chin J Hematol. 2012;33(11):975–7.Google Scholar
  8. 8.
    Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93.CrossRefPubMedGoogle Scholar
  9. 9.
    Thrombosis, Hemostasis Group HSCMA. Consensus of Chinese experts on diagnosis and treatment of adult primary immune thrombocytopenia (version 2016). Zhonghua Xue Ye Xue Za Zhi. 2016;37(2):89–93.Google Scholar
  10. 10.
    Wang XQ. Prospective clinical study of diagnosis and classification for 282 cases with primary myelodysplastic syndrome. Zhonghua Xue Ye Xue Za Zhi. 2006;27(8):546–9.PubMedGoogle Scholar
  11. 11.
    Kuendgen A, Matsuda A, Germing U. Differences in epidemiology of MDS between Western and Eastern countries: ethnic differences or environmental influence? Leuk Res. 2007;31(1):103–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of aplastic anemia (2017. Zhonghua Xue Ye Xue Za Zhi. 2017;38(1):1–5.Google Scholar
  13. 13.
    Salama A, Rieke M, Kiesewetter H, von Depka M. Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Ann Hematol. 2009;88(1):11–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296–302 (quiz 370).CrossRefPubMedGoogle Scholar
  15. 15.
    Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4):1401–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Matschke J, Muller-Beissenhirtz H, Novotny J, Vester I, Hertenstein B, Eisele L, et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naive adult patients with immune thrombocytopenia: EIS 2002 study. Acta Haematol. 2016;136(2):101–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Ben-Yehuda D, Gillis S, Eldor A. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematol. 1994;91(1):1–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the cooperative latin american group on hemostasis and thrombosis. Blood. 1984;64(6):1179–83.PubMedGoogle Scholar
  19. 19.
    Wang S, Yang R, Zou P, Hou M, Wu D, Shen Z, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012;96(2):222–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang M, Liu YF, Sun H, Xie XS, Ma J, Gan SL, et al. Clinical analysis of recombinant human thrombopoietin for treatment of 46 adult patients with newly diagnosed primary immune thrombocytopenia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(2):531–5.PubMedGoogle Scholar
  21. 21.
    Liu X, Huang Y, Liu W, Chen Y, Xue F, Zhang L, et al. Clinical analysis of recombinant human thrombopoietin for 92 adults with severe primary immune thrombocytopenia. Zhonghua Xue Ye Xue Za Zhi. 2015;36(4):312–5.PubMedGoogle Scholar
  22. 22.
    Hua B, Zhao Y, Wang S, Zhu T, Zhao Y. Development of recombinant human thrombopoietin antibodies following multi-dosing, subcutaneously medication in thrombocytopenic patients. Chin J Thromb Hemostasis. 2005;11(2):59–61.Google Scholar
  23. 23.
    Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–47.CrossRefPubMedGoogle Scholar
  24. 24.
    Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2009;373(9664):641–8.CrossRefGoogle Scholar
  25. 25.
    Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet (London, England). 2011;377(9763):393–402.CrossRefGoogle Scholar
  26. 26.
    Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–45.CrossRefPubMedGoogle Scholar
  27. 27.
    Yang R, Li J, Jin J, Huang M, Yu Z, Xu X, et al. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol. 2017;176(1):101–10.CrossRefPubMedGoogle Scholar
  28. 28.
    Gonzalez-Lopez TJ, Alvarez-Roman MT, Pascual C, Sanchez-Gonzalez B, Fernandez-Fuentes F, Jarque I, et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016;97(3):297–302.CrossRefPubMedGoogle Scholar
  29. 29.
    Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, et al. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol. 2016;95(2):239–44.CrossRefPubMedGoogle Scholar
  30. 30.
    Elgebaly AS, Ashal GE, Elfil M, Menshawy A. Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia. Clin Appl Thromb Hemost. 2017;23(8):928–37.  https://doi.org/10.1177/1076029616663849.CrossRefPubMedGoogle Scholar
  31. 31.
    Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (London, England). 2008;371(9610):395–403.CrossRefGoogle Scholar
  32. 32.
    Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–71.CrossRefPubMedGoogle Scholar
  33. 33.
    George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009;144(3):409–15.CrossRefPubMedGoogle Scholar
  34. 34.
    Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag DR, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–99.CrossRefPubMedGoogle Scholar
  35. 35.
    Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118(16):4338–45.CrossRefPubMedGoogle Scholar
  36. 36.
    Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–23.CrossRefPubMedGoogle Scholar
  37. 37.
    Cines DB, Gernsheimer T, Wasser J, Godeau B, Provan D, Lyons R, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol. 2015;102(3):259–70.CrossRefPubMedGoogle Scholar
  38. 38.
    Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25–33.CrossRefPubMedGoogle Scholar
  39. 39.
    Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999–1004.CrossRefPubMedGoogle Scholar
  40. 40.
    Arnold DM, Heddle NM, Carruthers J, Cook DJ, Crowther MA, Meyer RM, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119(6):1356–62.CrossRefPubMedGoogle Scholar
  41. 41.
    Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol. 2012;158(3):386–98.CrossRefPubMedGoogle Scholar
  42. 42.
    Patel VL, Mahevas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–95.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than 2 years duration. Haematologica. 2014;99(7):1264–71.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard JF, Cheze S, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228–36.CrossRefPubMedGoogle Scholar
  45. 45.
    Ghanima W, Khelif A, Waage A, Michel M, Tjonnfjord GE, Romdhan NB, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2015;385(9978):1653–61.CrossRefGoogle Scholar
  46. 46.
    Fianchi L, Rossi E, Murri R, De Stefano V, Pagano L, Leone G. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol. 2007;86(3):225–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93(6):930–3.CrossRefPubMedGoogle Scholar
  48. 48.
    Zhou H, Xu M, Qin P, Zhang HY, Yuan CL, Zhao HG, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541–7.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623–34.CrossRefPubMedGoogle Scholar
  50. 50.
    Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005;90(1):72–7.PubMedGoogle Scholar
  51. 51.
    Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121(23):4782–90.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990;74(2):223–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Emilia G, Morselli M, Luppi M, Longo G, Marasca R, Gandini G, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99(4):1482–5.CrossRefPubMedGoogle Scholar
  54. 54.
    Maloisel F, Andres E, Zimmer J, Noel E, Zamfir A, Koumarianou A, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116(9):590–4.CrossRefPubMedGoogle Scholar
  55. 55.
    Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75(1):60–4.CrossRefPubMedGoogle Scholar
  56. 56.
    George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3–40.PubMedGoogle Scholar
  57. 57.
    Szczepanik AB, Sikorska A, Slomkowski M, Konopka L. The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. Int J Lab Hematol. 2007;29(5):347–51.CrossRefPubMedGoogle Scholar
  58. 58.
    Xiao S, Liu Q, Hou M. Comparative study between two bleeding grading systems of primary immune thrombocytopenia. Zhonghua Xue Ye Xue Za Zhi. 2017;38(5):394–8.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Xin-guang Liu
    • 1
  • Xiao-chuan Bai
    • 2
  • Fang-ping Chen
    • 3
  • Yun-feng Cheng
    • 4
  • Ke-sheng Dai
    • 5
  • Mei-yun Fang
    • 6
  • Jian-Ming Feng
    • 7
  • Yu-ping Gong
    • 8
  • Tao Guo
    • 9
  • Xin-hong Guo
    • 10
  • Yue Han
    • 5
  • Luo-jia Hong
    • 11
  • Yu Hu
    • 9
  • Bao-lai Hua
    • 12
  • Rui-bing Huang
    • 13
  • Yan Li
    • 14
  • Jun Peng
    • 1
  • Mi-mi Shu
    • 15
  • Jing Sun
    • 16
  • Pei-yan Sun
    • 17
  • Yu-qian Sun
    • 18
  • Chun-sen Wang
    • 19
  • Shu-jie Wang
    • 20
  • Xiao-min Wang
    • 21
  • Cong-ming Wu
    • 22
  • Wen-man Wu
    • 23
  • Zhen-yu Yan
    • 24
  • Feng-e Yang
    • 25
  • Lin-hua Yang
    • 26
  • Ren-Chi Yang
    • 27
  • Tong-hua Yang
    • 28
  • Xu Ye
    • 29
  • Guang-sen Zhang
    • 30
  • Lei Zhang
    • 27
  • Chang-cheng Zheng
    • 31
  • Hu Zhou
    • 32
  • Min Zhou
    • 33
  • Rong-fu Zhou
    • 34
  • Ze-ping Zhou
    • 35
  • Hong-li Zhu
    • 36
  • Tie-nan Zhu
    • 20
  • Ming Hou
    • 1
  1. 1.Department of Hematology, Qilu HospitalShandong UniversityJinanChina
  2. 2.General Hospital of Ningxia Medical UniversityYinchuanChina
  3. 3.Xiangya HospitalCentre South UniversityChangshaChina
  4. 4.Zhongshan HospitalFudan UniversityShanghaiChina
  5. 5.The First Affiliated Hospital of Soochow UniversitySuzhouChina
  6. 6.The First Affiliated Hospital of Dalian Medical UniversityDalianChina
  7. 7.Qinghai Provincial People’s HospitalXiningChina
  8. 8.West China HospitalSichuan UniversityChengduChina
  9. 9.Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  10. 10.The First Affiliated Hospital of Xinjiang Medical UniversityÜrümqiChina
  11. 11.Harbin the Fourth HospitalHarbinChina
  12. 12.Northern Jiangsu People’s HospitalYangzhouChina
  13. 13.The First Affiliated Hospital of Nanchang UniversityNanchangChina
  14. 14.The First Hospital of Chinese Medical UniversityShenyangChina
  15. 15.Xijing HospitalThe Fourth Military Medical UniversityXi’anChina
  16. 16.Nanfang HospitalNanfang Medical UniversityGuangzhouChina
  17. 17.Xinqiao HospitalThe Third Military Medical UniversityChongqingChina
  18. 18.Peking University People’s HospitalBeijingChina
  19. 19.Sichuan Provincial People’s HospitalChengduChina
  20. 20.Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  21. 21.People’s Hospital of Xinjiang Uygur Autonomous RegionÜrümqiChina
  22. 22.Hainan Provincial People’s HospitalHaikouChina
  23. 23.Ruijin HospitalShanghai Jiao Tong UniversityShanghaiChina
  24. 24.Affiliated Hospital of North China University of Science and TechnologyTangshanChina
  25. 25.Union Hospital of Fujian Medical UniversityFuzhouChina
  26. 26.The Second Hospital of Shanxi Medical UniversityTaiyuanChina
  27. 27.Institute of Haematology and Blood Diseases HospitalChinese Academy of Medical SciencesTianjinChina
  28. 28.The First People’s Hospital of Yunnan ProvinceKunmingChina
  29. 29.The Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhouChina
  30. 30.The Second Xiangya HospitalCentral South UniversityChangshaChina
  31. 31.Anhui Provincial HospitalHefeiChina
  32. 32.Henan Cancer HospitalZhengzhouChina
  33. 33.Chengdu Women and Children’s HospitalChengduChina
  34. 34.Nanjing Drum Tower HospitalNanjingChina
  35. 35.The Second Affiliated Hospital of Kunming Medical UniversityKunmingChina
  36. 36.Chinese PLA General HospitalBeijingChina

Personalised recommendations